

Registered Office:

A-1106, Empire Business Hub, Nr. AUDA Water Tank, Science City Road, Sola, Ahmedabad-380060, Gujarat, India CIN No.: L24230GJ2012PLC071299

Date: 28th April, 2023

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001.

Dear Sir / Madam,

Sub: Newspaper advertisement of extract of notice of Rights Issue Ref: Security Id: EARUM / Code: 542724

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 84 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Company has given Newspaper Advertisement on 28th April, 2023 of notice of Rights Issue of Equity Shares.

Kindly take the same on your record and oblige us.

Thanking You.

For, Earum Pharmaceuticals Limited

Bhumishth Patel Director DIN: 02516641

Phone: +91-79-48402525 | Email: info@earumpharma.com | Web.: www.earumpharma.com

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A 1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** LAST DATE FOR MARKET RENUNCIATION* **ISSUE OPENS ON** ISSUE CLOSES ON ** 2" May, 2023 26" May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

*Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2/- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 202 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI circulars bearing to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer,

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shareholders, among others, who had been supplied to the state of Escrow Demat Account (Account Number -1201910105835556) In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity

Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions application by the Resident Eligible Equity Shareholders holding Equity Share sin physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shareholders h PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for the Application Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the Registrar with the help of the helptine number (D22-6263-8200) and their email address at rights issue@bigshareonline.com.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023.

DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue, and physically through registered post on 27th April, 2023 by the Registrar to the Issue, CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the EPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the EPF authority; or (b) the demat account of the Eligible Equity Shares held in the account of the Epistrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to the Application to such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

. Name of our Company, being Earum Pharmaceuticals Limited; 2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);

3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and the Eligible Equity Shareholder in case of joint names, irrespective of the Eligible Equity Shareholder and the Eligible Equity Shareholder in case of joint names and the Eligible Equity Shareholder in case of joint names.

5. Number of Equity Shares held as on Record Date:

Allotment option - only dematerialized form

. Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements;

9. Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); 10. Total number of Equity Shares applied for;

11. Total amount paid at the rate of Rs. 2)-per Equity Share;

12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained,

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

16. All such Eligible Equity Shareholders are deemed to have accepted the following: "If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

I/ We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act. I/ We (ii) am/ are, and the person, if any, for whose account (i we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.), and (iii) is/ are acquiring the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected. Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date. If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee

thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue- Basis of Allotment" on page 142. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer the "Off Market Renunciation"). Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

On Market Renunciation The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Right's Entitlements are tradable in dematerialized form only. The market lot for trading of Right's Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demant

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBI.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date. The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demant account. The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASER OF RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION AN APPLICATION AN APPLICATION AND FOR SUBSCRIBING THE RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE.

WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE REGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER Listing and trading of the Equity Shares to be issued pursuant to this Issue

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges.

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid up Rights Equity Shares to the Eligible Equity Shares would be suspended under the applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL. The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company to use the Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:

l. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription (acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever."

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below.

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address; the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders who have provided Indian address. Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent of Offer will be sent of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail. address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (II) Our Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

2. Off Market Renunciation

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number lin case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of Je-mail address I phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com

Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

REGISTRAR TO THE ISSUE BIGSHARE SERVICES PRIVATE LIMITED

BANKER TO AN ISSUE AXIS BANK LIMITED Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency,

Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 IskonAmbli Road, Ahmedabad - 380058 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Email: iskonambliroadahmedabad,branchhead@axisbank.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya SEBI Registration No: INR000001385 CIN: L65110GJ1993PLC020769

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in the United States for sal Rights Equity Shares in the United States.

BENGALURU

For, Earum PharmaceuticalsLimited

Madhuri Mistry Company Secretary

financialexp.ep. . in

Date:27th April, 2023

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").

EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited Company and according to the name of our Company was changed to "Earum Pharmaceuticals Private Limited Company and according to the name of our Company and a Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L24230GJ2012PLC071299, Registered Office: A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** LAST DATE FOR MARKET RENUNCIATION* **ISSUE OPENS ON** ISSUE CLOSES ON"" 2" May, 2023 31" May, 2023 26" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Classing Date.

**Our Board or a duly authorized committee thereof will have the right to extend the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24.67, 16.400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/ EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. "Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA *Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICOR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated July 24, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130 of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense Escrow Demat Account (Account Number -1201910105835558)

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatority required to use either the ASBA process. Shareholders should carefully read the provisions application by the Resident Eligible Equity Shareholders holding Equity Share sin physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shareholders h

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from

any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper Application for the Designated Branch of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper Application for the Designated Branch of the Registrar, Stock Exchanges. maintained with the same SCSB. Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for the Application Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders

holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

They may also communicate with the Registrar with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com. ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023.

DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue,

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shareholders holding the Equity Shareholders which would comprise Rights Entitlement Suspense Escrow Demat Account") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the IEPF authority; or (c) Equity Shares held in the account of the Equity Shares held in the account of the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares held in the IEPF authority; or (c) Equity Shares h by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars: Name of our Company, being Earum Pharmaceuticals Limited;

Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);

 Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for pursuant to this Issue

Number of Equity Shares held as on Record Date; Altorment option – only dematerialized form;

7. Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements;

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);

Total number of Equity Shares applied for; Total amount paid at the rate of Rs. 21- per Equity Share;

12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

If We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. If We (i) am/ are, and the person, if any, for whose account I/ we am) are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

If We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as application, such Applications pertaining to Rights Entitlements credited to the same demat account, as application forms along with a plain paper Application forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application forms along with a plain paper Application forms are submitted for Application for Application forms are submitted for Application forms are submitted for Application for Application

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date (or such period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee. thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number.

PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS: The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation"); or (b) through an off-market Renunciation"); or (c) the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation"); or (c) through an off-market Renunciation"); or (c) through an off-market Renunciation (c) the Stock Exchanges (the "Off Market Renunciation"); or (c) through an off-market Renunciation (c) the Stock Exchanges (the "Off Market Renunciation"); or (c) through an off-market Renunciation (c) through an off-market Renunciati Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders. Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company. In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Rights Entitlements are tradable in dematerialized form only. The market for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demat

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on "T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade for trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBI.

2. Off Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements who desire to transfer the Rights Entitlements who desire to transfer the Rights Entitlements who desire to transfer the Rights Entitlements who desire to the Rights Entitlements who desired the R receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demoit account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE RIGHTS EQUITY SHARES. IF NO APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS.

FOR PROCEDUREOF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER. Listing and trading of the Equity Shares to be issued pursuant to this Issue

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid-up Rights Equity Shares to the Eligible Equity Shares would be suspended under applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges.

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL. The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblock the respective ASBA Accounts, the entire monies received/blocked within fourdays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded/ unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

DISCLAIMER CLAUSE OF SEBI The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid

permission to this Company. The Exchange does not in any manner:

 Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii, warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company; and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and shall not have any claim against the Exchange whatsoever by reason of any loss which may be

suffered by such person consequent to or in connection with such subscription acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent / dispatched only to the Eligible Equity Shareholders who have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent I dispatched to the Eligible Equity Shareholders have not provided their e-mail address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail. address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

(I) Our Company at www.earumpharma.com; (ii) The Registrar at www.bigshareonline.com;

(iii) The Stock Exchanges at www.bseindia.com.

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DPID and Client ID or Folio Number (in case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS. KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online I electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of / e-mail address / phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com

Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form; www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders; www.bigshareonline.com

REGISTRAR TO THE ISSUE BANKER TO AN ISSUE **BIGSHARE SERVICES PRIVATE LIMITED AXIS BANK LIMITED** Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad – 380058 Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Website: www.bigshareonline.com Email: iskonambliroadahmedahad.branchhead@axisbank.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769 SEBI Registration No: INR000001385

Place: Ahmedabad

Date: 27th April, 2023

For, Earum PharmaceuticalsLimited Madhuri Mistry Company Secretary

Chandigarh

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange where the Equity Shares are listed i.e. BSE at www.bseindia.com and the website of the RTA i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in this announcement may not be offered or sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any public sale in any jurisdiction and any sale in any jurisdiction and any sale in any jurisdiction and an Rights Equity Shares in the United States.



FRIDAY, APRIL 28, 2023

FINANCIAL EXPRESS

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A 1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** LAST DATE FOR MARKET RENUNCIATION* **ISSUE OPENS ON** ISSUE CLOSES ON ** 2" May, 2023 26" May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

*Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2/- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 202 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI circulars bearing to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer,

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shareholders, among others, who had been supplied to the state of Escrow Demat Account (Account Number -1201910105835556)

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions application by the Resident Eligible Equity Shareholders holding Equity Share sin physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shareholders h PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to obtain it from

any other source may make an Application to subscribe to this Issue on plain paper with the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for the Application Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the Registrar with the help of the helptine number (D22-6263-8200) and their email address at rights issue@bigshareonline.com.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue, and physically through registered post on 27th April, 2023 by the Registrar to the Issue,

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the EPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the EPF authority; or (b) the demat account of the Eligible Equity Shares held in the account of the Epistrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to the Application to such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

. Name of our Company, being Earum Pharmaceuticals Limited;

2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository); 3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and the Eligible Equity Shareholder in case of joint names, irrespective of the Eligible Equity Shareholder and the Eligible Equity Shareholder in case of joint names and the Eligible Equity Shareholder in case of joint names.

5. Number of Equity Shares held as on Record Date: Allotment option - only dematerialized form

. Number of Equity Shares entitled to:

2. Off Market Renunciation

Number of Equity Shares applied for within the Rights Entitlements; 9. Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);

10. Total number of Equity Shares applied for;

11. Total amount paid at the rate of Rs. 2)-per Equity Share; 12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained,

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence. I/ We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act.

I/ We (ii) am/ are, and the person, if any, for whose account (i we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.), and (iii) is/ are acquiring the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements." In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date. If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee

thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue- Basis of Allotment" on page 142. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer the "Off Market Renunciation"). Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

On Market Renunciation The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Right's Entitlements are tradable in dematerialized form only. The market lot for trading of Right's Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demant

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBI.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer. receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demant account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASER OF RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION AN APPLICATION AN APPLICATION AND FOR SUBSCRIBING THE RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE REGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading

of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof. For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid up Rights Equity Shares to the Eligible Equity Shares would be suspended under the applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges.

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL. The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company to use the Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid

permission to this Company. The Exchange does not in any manner:

l. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

Listing and trading of the Equity Shares to be issued pursuant to this Issue

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription (acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever." Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:

In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address; the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders who have provided Indian address. Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e mail address, then the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent of Offer will be sent of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail. address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

(I) Our Company at www.earumpharma.com; (ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number lin case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company. Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF.

OTHER IMPORTANTLINKS AND HELPLINE: The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com

Updation of Je-mail address I phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

REGISTRAR TO THE ISSUE **BANKER TO AN ISSUE** BIGSHARE SERVICES PRIVATE LIMITED **AXIS BANK LIMITED** Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Email: iskonambliroadahmedabad,branchhead@axisbank.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya SEBI Registration No: INR000001385

Madhuri Mistry Company Secretary Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in the United States for sal



CIN: L65110GJ1993PLC020769



For, Earum PharmaceuticalsLimited

Rights Equity Shares in the United States.

Date:27th April, 2023

FRIDAY, APRIL 28, 2023

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited Company and according to the Pharmaceutical Private Limited Company and according to the Pharmaceutical Private Limited Company and according to the Pharmaceutical Private Limited Company and accordin Pharmaceuticals Limited pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L24230GJ2012PLC071299, Registered Office: A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** ISSUE OPENS ON LAST DATE FOR MARKET RENUNCIATION* ISSUE CLOSES ON ** 2" May, 2023 31" May, 2023 26" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

"Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24.67.16.400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 21. EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 21. PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49.34.32,8001. ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER." Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing re reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated July 24, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/ CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130 of the Letter of Offer,

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue are

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shareholders, among others, who have a state of the state of

Escrow Demat Account (Account Number -1201910105835556) In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity

Shares against their Rights Entitlements with respect to the equity shares held in physical form. PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICOR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details of procedure for application by the Resident Eligible Equity Shareholders holding Equity Shares in physical form on page 130 of the Letter of Offer.

PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from

any other source may make an Application to subscribe to this issue on plain paper with the same details as per the Application form that is available on the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. maintained with the same SCSB. Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue. CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shareholders holding the Equity Shareholders which would comprise Rights Entitlement Suspense Escrow Demat Account*) opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the Eligible Equity Shares which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shares held in the account of the Eligible Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional

holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

They may also communicate with the Registrar with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com.

equity shareholders in the United States. APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the Office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

I. Name of our Company, being Earum Pharmaceuticals Limited:

. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository); 3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Number of Equity Shares held as on Record Date:

2. Off Market Renunciation

Number of Equity Shares entitled to;

Number of Equity Shares applied for within the Rights Entitlements;

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); 10. Total number of Equity Shares applied for; 11. Total amount paid at the rate of Rs. 2/- per Equity Share;

 Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained;

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

 Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and

each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence. If We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction not subject to, the registration requirements of the US Securities Act.

If We (i) am/ are, and the person, if any, for whose account If we am) are acquiring such Rights Entitlement and/ or the Rights Equity Shares is are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

If We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as application Forms afong with a plain paper Application, such Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms afong with a plain paper Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense account

Shareholders are requested to strictly adhere to these instructions, Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com. Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee

thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number.

PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS: The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market Renunciation Period. The Shareholders should have the demat Rights

Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism. Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date. On Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive). The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements and their demant they intend to trade. The Shareholder scan place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demant.

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + Frolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements. of the Stock Exchanges and the SEBI.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to the Rights Entitlemen

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time. ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE RIGHTS EQUITY SHARES. IF NO APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON

OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE CREDITED. EVEN IF SUCH RIGHTS ENTITLEMENTS WERE PURCHASED FROM MARKET AND THE PURCHASER WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER.

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights Equity Shares Allotted pursuant to this issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully Shares to the Eligible Equity Shares to the Eligible Equity Shares would be suspended under applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule. In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means junblock the respective ASBA Accounts, the entire monies received/blocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within

fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law. DISCLAIMER CLAUSE OF SEBI The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size of issue is below Rs. 5000 Lakhs.

DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE): As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below:

"BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company to use the Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:

 Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii, warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

Listing and trading of the Equity Shares to be issued pursuant to this Issue

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be

suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever." Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:

In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent / dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address, then the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent / dispatched to the Eligible Equity Shareholders have provided Indian address and who have made a request in this regard. In case such Eligible Equity Shareholders have not provided their e-mail address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (I) Our Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of our Company.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible. BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED

MONITORING AGENCY: Not Applicable FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online | electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of / e-mail address / ghone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com

Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com REGISTRAR TO THE ISSUE

BANKER TO AN ISSUE BIGSHARE SERVICES PRIVATE LIMITED AXIS BANK LIMITED Pinnacle Business Park, Office No S8-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Website: www.bigshareonline.com Email: iskonambliroadahmedabad.branchhead@axisbank.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com SEBI Registration No: INRODO001385 Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769 Date: 27th April, 2023 For, Earum PharmaceuticalsLimited

Place: Ahmedabad

addresses provided by them.

Madhuri Mistry Company Secretary

New Delhi

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. BSE at www.bseindia.com and the website of the RTA

i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction. Rights Equity Shares in the United States. financialexp.ep

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").

FRIDAY, APRIL 28, 2023

Madhuri Mistry Company Secretary

HYDERABAD

EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A 1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** LAST DATE FOR MARKET RENUNCIATION* **ISSUE OPENS ON** ISSUE CLOSES ON ** 2" May, 2023 26" May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

*Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2/- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 202 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI circulars bearing to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer,

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shareholders, among others, who had been supplied to the state of Escrow Demat Account (Account Number -1201910105835556) In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity

Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions application by the Resident Eligible Equity Shareholders holding Equity Share sin physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shareholders h PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

any other source may make an Application to subscribe to this Issue on plain paper with the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for the Application Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the Registrar with the help of the helptine number (D22-6263-8200) and their email address at rights issue@bigshareonline.com.

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to obtain it from

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue, and physically through registered post on 27th April, 2023 by the Registrar to the Issue,

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the EPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the EPF authority; or (b) the demat account of the Eligible Equity Shares held in the account of the Epistrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to the Application to such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars: . Name of our Company, being Earum Pharmaceuticals Limited;

2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository); 3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and the Eligible Equity Shareholder in case of joint names, irrespective of the Eligible Equity Shareholder and the Eligible Equity Shareholder in case of joint names and the Eligible Equity Shareholder in case of joint names. 5. Number of Equity Shares held as on Record Date:

Allotment option - only dematerialized form . Number of Equity Shares entitled to:

Number of Equity Shares applied for within the Rights Entitlements; 9. Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); 10. Total number of Equity Shares applied for;

11. Total amount paid at the rate of Rs. 2)-per Equity Share;

12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained,

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

I/ We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act.

I/ We (ii) am/ are, and the person, if any, for whose account (i we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.), and (iii) is/ are acquiring the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations. I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com. Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date.

If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue- Basis of Allotment" on page 142.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer the "Off Market Renunciation"). Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism. Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders. Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

On Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company. In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Right's Entitlements are tradable in dematerialized form only. The market lot for trading of Right's Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demant

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBI.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date. The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demant account. The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASER OF RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION AN APPLICATION AN APPLICATION AND FOR SUBSCRIBING THE RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE.

WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE REGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER Listing and trading of the Equity Shares to be issued pursuant to this Issue

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges.

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof. For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid up Rights Equity Shares to the Eligible Equity Shares would be suspended under the applicable law.

The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule. In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company to use the Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid

permission to this Company. The Exchange does not in any manner:

l. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription (acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever."

Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:

In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address; the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders who have provided Indian address.

Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian Further, this Final Letter of Offer will be sent of Offer will be sent of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail.

address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (II) Our Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

2. Off Market Renunciation

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online.

Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number lin case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company. Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED

MONITORING AGENCY: Not Applicable FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF.

OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of Je-mail address I phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com

Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

REGISTRAR TO THE ISSUE BIGSHARE SERVICES PRIVATE LIMITED Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093

BANKER TO AN ISSUE AXIS BANK LIMITED Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058

Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Email: iskonambliroadahmedabad,branchhead@axisbank.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya SEBI Registration No: INR000001385 CIN: L65110GJ1993PLC020769 Date:27th April, 2023 For, Earum PharmaceuticalsLimited

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in the United States for sal Rights Equity Shares in the United States.



FRIDAY, APRIL 28, 2023

FINANCIAL EXPRESS

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A 1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME** LAST DATE FOR MARKET RENUNCIATION* **ISSUE OPENS ON** ISSUE CLOSES ON ** 2" May, 2023 26" May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

*Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2/- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/136 dated January 19, 202 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI circulars bearing to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer,

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shareholders, among others, who had been supplied to the state of Escrow Demat Account (Account Number -1201910105835556)

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions application by the Resident Eligible Equity Shareholders holding Equity Share sin physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shareholders h PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to obtain it from

any other source may make an Application to subscribe to this Issue on plain paper with the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for the Application Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the Registrar with the help of the helptine number (D22-6263-8200) and their email address at rights issue@bigshareonline.com.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue, and physically through registered post on 27th April, 2023 by the Registrar to the Issue,

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the EPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the EPF authority; or (b) the demat account of the Eligible Equity Shares held in the account of the Epistrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to this Issue on plain paper with the same details as per the Application to subscribe to the Application to such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

. Name of our Company, being Earum Pharmaceuticals Limited;

2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository); 3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the Equity Shareholder and the Eligible Equity Shareholder in case of joint names, irrespective of the Eligible Equity Shareholder and the Eligible Equity Shareholder in case of joint names and the Eligible Equity Shareholder in case of joint names.

5. Number of Equity Shares held as on Record Date: Allotment option - only dematerialized form

. Number of Equity Shares entitled to:

2. Off Market Renunciation

Number of Equity Shares applied for within the Rights Entitlements; 9. Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);

10. Total number of Equity Shares applied for;

11. Total amount paid at the rate of Rs. 2)-per Equity Share; 12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained,

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence. I/ We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act.

I/ We (ii) am/ are, and the person, if any, for whose account (i we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.), and (iii) is/ are acquiring the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements." In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date. If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee

thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue- Basis of Allotment" on page 142. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer the "Off Market Renunciation"). Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

On Market Renunciation The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Right's Entitlements are tradable in dematerialized form only. The market lot for trading of Right's Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demant

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBI.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer. receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demant account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASER OF RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION AN APPLICATION AN APPLICATION AND FOR SUBSCRIBING THE RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE REGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading

of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof. For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid up Rights Equity Shares to the Eligible Equity Shares would be suspended under the applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges.

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL. The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company to use the Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid

permission to this Company. The Exchange does not in any manner:

l. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

Listing and trading of the Equity Shares to be issued pursuant to this Issue

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription (acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever." Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:

In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address; the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent | dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders who have provided Indian address. Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e mail address, then the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent of Offer will be sent of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail. address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

(I) Our Company at www.earumpharma.com; (ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number lin case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company. Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF.

OTHER IMPORTANTLINKS AND HELPLINE: The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com

Updation of Je-mail address I phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

REGISTRAR TO THE ISSUE **BANKER TO AN ISSUE** BIGSHARE SERVICES PRIVATE LIMITED **AXIS BANK LIMITED** Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Email: iskonambliroadahmedabad,branchhead@axisbank.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya SEBI Registration No: INR000001385

Madhuri Mistry Company Secretary Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in any jurisdiction in the United States for sale in the United States for sal



CIN: L65110GJ1993PLC020769



For, Earum PharmaceuticalsLimited

Rights Equity Shares in the United States.

Date:27th April, 2023

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").

EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly the name of our Company was converted into a Public Limited Company and accordingly to the name of our Company and accordingly to Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079 48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

ISSUE PROGRAMME		
ISSUE OPENS ON	LAST DATE FOR MARKET RENUNCIATION*	ISSUE CLOSES ON**
2" May, 2023	26° May, 2023	31" May, 2023

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

**Our Board or a duly authorized committee thereof will have the right to extend the Issue Dening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24.67.16.400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUE PRICE"), AGGREGATING UPTO RS. 49.34.32.800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER." Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA 'Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICOR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated July 24, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense Escrow Demat Account (Account Number -1201910105835556) In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity

Shares against their Rights Entitlements with respect to the equity shares held in physical form. PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application

through ASBA. For details of procedure for application by the Resident Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form" on page 130of the Letter of Offer. An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from

maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization to the SCSB, via the electronic mode, for blocking funds in the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI ICDR Regulations. holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

They may also communicate with the Registrar with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com.

any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application form that is available on the Website of the Registrar, Stock Exchanges. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023.

DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue,

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account") opened by our Company, for the Eligible Equity Shareholders which are suspense account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Suspense Escrow Dematerialised form; and (ii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Suspense Escrow Dematerialised form; and (iii) a demat suspense escrow Dematerialised form; and (iii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Dematerialised form; and (iii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Dematerialised form; and (iii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Dematerialised form; and (iii) a demater by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars: Name of our Company, being Earum Pharmaceuticals Limited;

Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);

Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for pursuant to this Issue Number of Equity Shares held as on Record Date;

Altorment option – only dematerialized form;

Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements;

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);

Total number of Equity Shares applied for; Total amount paid at the rate of Rs. 2/- per Equity Share;

12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and All such Eligible Equity Shareholders are deemed to have accepted the following: "I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and

If We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act.

If We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations. I/ We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as application, such Applications pertaining to Rights Entitlements credited to the same demat account, as application Forms along with a plain paper Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submitted for Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submitted for Application Forms are submitted for Application Forms

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date (or such period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number.

PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS: The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market Renunciation Period. The Shareholders should have the demat Rights Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICOR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO606200 15 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements available in their demat to trade. The Shareholder scan place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat

of the Stock Exchanges and the SEBI. 2. Off Market Renunciation

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on "T+1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements who desire to transfer the Rights Entitlements who desire to transfer the Rights Entitlements who desire to transfer the Rights Entitlements who desire to the Rights Entitlements who desired the R receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demost account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE RIGHTS EQUITY SHARES. IF NO APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS.

FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER. Listing and trading of the Equity Shares to be issued pursuant to this Issue

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights Equity Shares Allotted pursuant to this Issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations, Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully gaid-up Rights Equity Shares to the Eligible Equity Shares would be suspended under applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INE060601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of such listing approvals, the Equity Shares shall be debited from such temporary ISIN and

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL. The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid

permission to this Company. The Exchange does not in any manner: Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or

ii, warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange what soever by reason of any loss which may be

suffered by such person consequent to or in connection with such subscription acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent of Offer will be sent of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail. address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (I) Our Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

DISCLAIMER CLAUSE OF SEBI

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online.

Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DPID and Client ID or Folio Number (in case of Eligible Equity Shareholders holding Equity Shareholders holdin Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of / e-mail address / phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com

Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form; www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders; www.bigshareonline.com

REGISTRAR TO THE ISSUE	BANKER TO AN ISSUE
BIGSHARE SERVICES PRIVATE LIMITED Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana SEBI Registration No: INR000001385	AXIS BANK LIMITED Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad – 380058 Tel: 8758474645 Email: iskonambliroadahmedabad.branchhead@axisbank.com Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769

Date: 27th April, 2023 Place: Ahmedabad

For, Earum PharmaceuticalsLimited Madhuri Mistry Company Secretary

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange where the Equity Shares are listed i.e. BSE at www.bseindia.com and the website of the RTA

Lucknow

i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in this announcement may not be offered or sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any properties of the United States and any prope Rights Equity Shares in the United States.



This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum." Pharmaceuticals Limited pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A-1106, Empire Business Hub. Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME ISSUE OPENS ON** LAST DATE FOR MARKET RENUNCIATION* ISSUE CLOSES ON ** 2" May, 2023 26" May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

**Our Board or a duly authorized committee thereof will have the right to extend the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2)- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2)- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER." Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! *Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020. SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated July 24, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/13 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Dirocess." Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense Escrow Demat Account (Account Number -1201910105835556) In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity

Shares against their Rights Entitlements with respect to the equity shares held in physical form. PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICOR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application

through ASBA. For details of procedure for application by the Resident Eligible Equity Shares in physical form ason the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form" on page 130 of the Letter of Offer.

PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account. maintained with the same SCSB.

APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Righ

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization to the Application Form, as the case may be, at the time of submission of the Application.

holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com. ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue has been completed in electronic mode through registered post on 27th April, 2023 by the Registrar to the Issue. CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account") opened by our Company, for the Eligible Equity Shares holders which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held

by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any, or (f) non-institutional equity shareholders in the United States. APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing

such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain pager will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States. Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

Name of our Company, being Earum Pharmaceuticals Limited;

Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);

3. Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible

Number of Equity Shares held as on Record Date;

. Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements;

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);

10. Total number of Equity Shares applied for; 11. Total amount paid at the rate of Rs. 2/- per Equity Share;

Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account number, name, address and branch of the SCSB with which the account is maintained;

Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

16. All such Eligible Equity Shareholders are deemed to have accepted the following: "If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

If We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transaction not subject to, the registration requirements of the US Securities Act.

If We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

If We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements." In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

If the Application Form is not submitted with an SCSBs, uploaded with the SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142.

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date, Our Board or any committee thereof may extend the Issue Opening Date (inclusive of the Issue Opening Date).

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market Renunciation"); or (b) through an off-market Renunciation"); or (c) through an off-market Renunciation (c) through an off-market R Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date. 1. On Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company. In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eigible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEOGO620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive). The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements available in their demants and the Rights Entitlements and the Rights Entitlements available in their demants. account.

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on "T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements. of the Stock Exchanges and the SEBI. 2. Off Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only, Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer of the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements who desired their Rights Entitlements who desired the Rights Entitlem receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demot account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE RIGHTS EQUITY SHARES. IF NO APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS.

Listing and trading of the Equity Shares to be issued pursuant to this Issue Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICOR Regulations, the Rights Equity Shares Allotted pursuant to this Issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and

FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER.

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBICDR Regulations. Our Company will approval from the BSE Limited through letter bearing reference number DCS/RIGHT/JR/FIP/3173/2022-23 dated March 2, 2023. Our Company will approval from the BSE Limited through letter bearing reference number DCS/RIGHT/JR/FIP/3173/2022-23 dated March 2, 2023. Our Company will approval from the BSE Limited through letter bearing reference number DCS/RIGHT/JR/FIP/3173/2022-23 dated March 2, 2023. Our Company will approval from the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof. For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid-up Rights Equity Shares to the Eligible Equity Shares to the Eligible Equity Shares action for crediting the fully paid-up Rights Equity Shares action for crediting the fully paid-up Rights Equity Shares to the Eligible Equity Shares action for crediting the fully paid-up Rights Equity Shares action for crediting the fully paid-up Rights Equity Shares action for crediting the fully paid-up Rights Equity Shares action for crediting the fully paid action for crediting the full action for cre

The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing trading approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule. In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblock the respective ASBA Accounts, the entire monies received/blocked within fourdays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within

fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer in default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

DISCLAIMER CLAUSE OF SEBI The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

"BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange has scrutinized this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner: I. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or

ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange what soever by reason of any loss which may be

Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below.

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICOR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent / dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below:

suffered by such person consequent to or in connection with such subscription acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever.

Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Further, this Final Letter of Offer will be sent / dispatched to the Eligible Equity Shareholders who have provided their valid e-mail address and who have made a request in this regard. In case such Eligible Equity Shareholders have not provided their e-mail

address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them, Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (I) Our Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com. Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online.

Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number (in case of Eligible Equity Shareholders holding Equity Shareholders holdi Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online | electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of (e-mail address) phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com

Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders; www.bigshareonline.com

REGISTRAR TO THE ISSUE

BIGSHARE SERVICES PRIVATE LIMITED Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana SEBI Registration No: INRODO001385

BANKER TO AN ISSUE AXIS BANK LIMITED

Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058 Tel: 8758474645 Email: iskonamblirgadahmedabad.branchhead@axisbank.com

Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769

Date: 27th April, 2023 Place: Ahmedahad

For, Earum PharmaceuticalsLimited Madhuri Mistry

Company Secretary Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer with Stock Exchange i.e. BSE at www.bseindia.com and the website of the RTA.

i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholders hould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States. Rights Equity Shares in the United States.



FRIDAY, APRIL 28, 2023

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").



EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited Company and according to the name of our Company and according to the name of o Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L242306J2012PLC071299, Registered Office: A 1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL **ISSUE PROGRAMME**

ISSUE OPENS ON LAST DATE FOR MARKET RENUNCIATION* ISSUE CLOSES ON ** 2" May, 2023 26° May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date. **Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time, provided that this Issue will not remain open in excess of 30 (Thirty) days from the Issue Determine from time to time, provided that this Issue Will not remain open in excess of 30 (Thirty) days from the Issue Opening Date.

ISSUE OF 24,67,16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2/- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER." Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! *Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI/HO/ CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/(CIR/P/2020) 13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130 of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company namely Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (Account Number - 1201910105835556)

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form,

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details of procedure for application by the Resident Eligible Equity Shares in physical form" on page 130of the Letter of Offer.

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account.

maintained with the same SCSB. Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization to the SCSB, via the electronic mode, for blocking funds in the Application.

APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date. They may also communicate with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights is sue@bigshareonline.com.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023. DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue has been completed in electronic mode through email on 24th April, 2023 and physically through registered post on 27th April, 2023 by the Registrar to the Issue.

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regula Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "Earum Pharmaceuticals Limited Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the Equity Shares held in the account of the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional

equity shareholders in the United States. APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

 Name of our Company, being Earum Pharmaceuticals Limited; Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
 Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) (DP and Client ID;

4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue

5. Number of Equity Shares held as on Record Date: Allotment option – only dematerialized form;

of the Stock Exchanges and the SEBI 2. Off Market Renunciation

Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements;

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); 10. Total number of Equity Shares applied for;

11. Total amount paid at the rate of Rs. 2)- per Equity Share;

Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;

14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

16. All such Eligible Equity Shareholders are deemed to have accepted the following: "If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and

each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence. If We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction not subject to, the registration requirements of the US Securities Act.

If We (i) am/ are, and the person, if any, for whose account If we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations."), and (iii) is/ are acquiring the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

If We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements. **

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as application Forms along with a plain paper Application, such Applications shall be liable to be rejected. Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date Committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date. If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number.

PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS: The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (b) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market Renunciation"); or (c) through an off-market transfer(the "Off Market Renunciation"); or (c) through an off-market Renunciation (the "Off Market Renunciation"); or (c) through an off-market Renunciation (the "Off Market Renunciation"); or (c) through an off-market Renunciation (the "Off Market Renunci

Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism. Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements as a result of trading in the Rights Entitlements.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders. Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company. In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Rights Entitlements are tradable in dematerialized form only. The market for for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to self their Rights Entitlements will have to do so through their registered stock brokers by quoting the Rights Entitlements only to the extent of Rights Entitlements available in their demat

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + Trolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights Entitlements will be a delivery instruction slip quoting the Rights En

receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account. The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASER OF RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION. AN APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE CARDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WILL BE CARDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WILL BE CARDITED, EVEN IF SUCH RIGHTS ENTITLEMENTS WILL BE CARDITED.

WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS. FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, OFF MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE LETTER OF OFFER.

Listing and trading of the Equity Shares to be issued pursuant to this Issue Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed as soon as practicable and all steps for completion of necessary formalities for listing and commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid-up Rights Equity Shares to the Eligible Equity Shares to the Eligible Equity Shares action for crediting the fully paid-up Rights Equity Shares would be suspended under the applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing approvals, the Equity Shares shall be debited from such temporary ISIN and

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means unblocked within four days of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

DISCLAIMER CLAUSE OF SEBI The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size of issue is below Rs. 5000 Lakhs.

DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE): As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below:

"BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange has scrutinized this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid. permission to this Company. The Exchange does not in any manner:

 Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever.

Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICOR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent (dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of

Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent / dispatched to the Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

(I) Our Company at www.earumpharma.com; (ii) The Registrar at www.bigshareonline.com;

(iii) The Stock Exchanges at www.bseindia.com. Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number (in case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible. BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE

The Investors canvisit following links for the below-mentioned purposes: Frequently asked questions and online / electronic dedicated Shareholders: www.bigshareonline.com

Updation of (e-mail address) phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com REGISTRAR TO THE ISSUE

Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093

Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana SEBI Registration No: INR000001385

BIGSHARE SERVICES PRIVATE LIMITED

BANKER TO AN ISSUE **AXIS BANK LIMITED**

CIN: L65110GJ1993PLC020769

Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad - 380058

Tel: 8758474645 Email: iskonambliroadahmedabad.branchhead@axisbank.com Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya

Date:27th April, 2023 Place: Ahmedabad

For, Earum PharmaceuticalsLimited Madhuri Mistry

Company Secretary

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE Limited. The Letter of Offer is available on the website of Stock Exchange where the Equity Shares are listed i.e. BSE at www.bigsharesonline.com and the website of the RTA i.e. Bigshare Services Private Limited atwww.bigsharesonline.com. Eligible Equity Sharesholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.









FRIDAY, APRIL 28, 2023

FINANCIAL EXPRESS

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").

EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly to the name of our Company and accordingly to the name of Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat.

Corporate Identification Number: L24230GJ2012PLC071299, Registered Office: A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL

ISSUE PROGRAMME ISSUE OPENS ON LAST DATE FOR MARKET RENUNCIATION* ISSUE CLOSES ON"" 2" May, 2023 26° May, 2023 31" May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date. **Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time, provided that this Issue will not remain open in excess of 30 (Thirty) days from the Issue Opening Date.

*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below.

ISSUE OF 24,67, 16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF RS. 2): FACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "COMPANY" O EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EV

SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER." Assuming full subscription with respect to Rights Equity Shares. Simple, Safe, Smart way of Application - Make useofit!!!

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/13 dated January 19, 2021, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2 CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this Issue are mandatonly required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer. Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shares in physical form, and whose demat account opened by our Company or the Registrar, shall be credited in a demat suspense escrow account opened by our Company namely Earum Pharmaceuticals Limited Rights Entitlement Suspense

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICOR Regulations, the SEBI ICOR Regulations, the SEBI Rights Issue are mandatorily required to use either the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application. through ASBA. For details of procedure for application by the Resident Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date i.e. April 10, 2023, see "Procedure for Application by Eligible Equity Shares in physical form as on the Record Date in the Record Date

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization Form, as the case may be, at the time of submission of the Application. APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their respective demat account to the Registrar or our Company at least one day before the Issue Closing Date.

They may also communicate with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com. ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023.

DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue has been completed in electronic mode through email on 24thApril, 2023 and physically through registered post on 27thApril, 2023 by the Registrar to the Issue. CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICOR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account of the Eligible Equity Shares hold in the account of the EPF authority; or (b) the demat accounts of the Eligible Equity Shares hold in the account (including those pursuant to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares hold by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional

APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

. Name of our Company, being Earum Pharmaceuticals Limited:

Escrow Demat Account (Account Number -1201910105835556)

Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
 Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID;

1. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible

. Number of Equity Shares held as on Record Date; Allotment option – only dematerialized form;

of the Stock Exchanges and the SEBI, 2. Off Market Renunciation

equity shareholders in the United States.

. Number of Equity Shares entitled to: Number of Equity Shares applied for within the Rights Entitlements:

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); Total number of Equity Shares applied for;

1. Total amount paid at the rate of Rs. 2)-per Equity Share;

12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;

15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

If We understand and agree that the Rights Entitlement and Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. If We (i) amf are, and the person, if any, for whose account I/ we amf are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I) We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications believed.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION: The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Opening Date, Our Board or any committee thereof may extend the said date for such period as it may determine the Issue Opening Date, Our Board or any committee the Issue Opening Date, Our Board or any committee the Issue Opening Date (Inc.).

If the Application Form is not submitted with an SCSBs, uploaded with the ScSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in this Final Letter of Offer shall be deemed to have been declined and our Board or any committee. thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue- Basis of Allotment" on page 142.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges, Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account.

PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS: The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the Secondary market platform of the Stock Exchanges (the "On Market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation"), during the Renunciation Period. The Shareholders should have the demat Rights

Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism. Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INEO6062001 5 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlement. The On Market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 to 31st May, 2023 (both days inclusive). The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements who desire to sell their Rights Entitlements who desire to sell their Rights Entitlements available in their demant.

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade for trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date. The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer. The buyer and the details of the Rights Entitlements who desire to transfer.

receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account. The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION I OFF MARKET RENUNCIATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS.

FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE LETTER OF OFFER.

Listing and trading of the Equity Shares to be issued pursuant to this Issue Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the Equity Shares Allotted pursuant to this Issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and

commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company has received in-principal approval from the BSE Limited through letter bearing reference number DCS/RIGHT/JR/FIP/3173/2022-23 dated March 2, 2023. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares of fered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid-up Rights Equity Shares to the Eligible Equity Shares to the Eligible Equity Shares action for crediting the fully paid-up Rights Equity Shares would be suspended under the applicable law.

The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INE060601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing trading approvals from the Stock Exchanges. Upon receipt of such listing and trading approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule. In case our Company fails to obtain listing or trading permission from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded/ unblocked within

fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law. DISCLAIMER CLAUSE OF SEBI

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange has scrutinized this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid.

permission to this Company. The Exchange does not in any manner: I. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or

ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

 Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company; and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange what seever by reason of any loss which may be

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below.

suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

DISPATCH AND AVAILABILITY OF ISSUE MATERIALS: In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent / dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights En

addresses provided by them. Further, this Final Letter of Offer will be sent / dispatched to the Eligible Equity Shareholders have provided Indian address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail

address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

(I) Our Company at www.earumpharma.com; (ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online. Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of our Company.

Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED MONITORING AGENCY: Not Applicable

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online I electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders; www.bigshareonline.com Updation of / e-mail address | phone or mobile number in the records maintained by the Registrar or our Company; www.bigshareonline.com

Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form; www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

BIGSHARE SERVICES PRIVATE LIMITED Pinnacle Business Park, Office No S6-2, 6th, Mahakali Cayes Rd, Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Vijay Surana SEBI Registration No: INR000001385

BANKER TO AN ISSUE AXIS BANK LIMITED Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadhevKishan Residency. Iskon Ambli Road, Ahmedabad - 380058 Tel: 8758474645 Email: iskonambliroadahmedabad.branchhead@axisbank.com Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769

Date:27th April, 2023 Place: Ahmedabad

REGISTRAR TO THE ISSUE

Madhuri Mistry

For, Earum PharmaceuticalsLimited

Company Secretary

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange where the Equity Shares are listed i.e. BSE at www.bseindia.com and the website of the RTA i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholders hould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.









This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement or the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the letter of offer dated April 19, 2023 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE").

EARUM PHARMACEUTICALS LIMITED

Our Company was originally incorporated on July 26, 2012, as "Earum Pharmaceuticals Private Limited" as a Private Limited Company was converted into a Public Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly the name of our Company was changed to "Earum Pharmaceuticals Private Limited" as a Private Limited Company and accordingly to the name of our Company and accordingly the name of our Company and accordingly to the name of our Company and accordingly to the name of our Company and according to the name of our Company and according to the name of our Company and accor Pharmaceuticals Limited" pursuant to a special resolution passed by our Shareholders at the EGM held on January 10, 2019. A fresh certificate of incorporation consequent upon conversion to Public Limited Company was issued on January 23, 2019 by Registrar of Companies, Ahmedabad, Gujarat

Corporate Identification Number: L24230GJ2012PLC071299, Registered Office: A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060, Telephone: + 079-48402525; Email id:cs@earumpharma.com, Website: www.earumpharma.com, Contact Person: Mrs. Madhuri Mistry, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY:MR. BHUMISHTH NARENDRABHAI PATEL AND MRS. PAYAL BHUMISHTH PATEL ISSUE PROGRAMME **ISSUE OPENS ON** LAST DATE FOR MARKET RENUNCIATION* ISSUE CLOSES ON" 2" May, 2023 31" May, 2023 26° May, 2023

* Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

**Dur Board or a duly authorized committee thereof will have the right to extend the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ISSUE OF 24,67, 16,400 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF Rs. 2)- EACH ("EQUITY SHARES") OF EARUM PHARMACEUTICALS LIMITED ("EARUM" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 2)- PER EQUITY SHARE ("ISSUE PRICE"), AGGREGATING UPTO RS. 49,34,32,800/- ON RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 4 (FOUR) FULLY PAID UP EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHARE HE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 125 OF THIS FINAL LETTER OF OFFER. Assuming full subscription with respect to Rights Equity Shares.

Simple, Safe, Smart way of Application - Make useofit!!! ASBA *Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blockingthe fund in the bank account, investors can avail the same. For further details read section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/136 dated July 24, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2021/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL1/CIR/P/2020/13 dated January 19, 2021 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 (Collectively hereafter referred to as "ASBA Circulars"), all Investors desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Procedure for Application through the ASBA Process" on page 128 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two working Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to procedure for participating in this Issue mentioned on page 130of the Letter of Offer.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account opened by our Company namely Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (Account Number -1201910105835556)

In accordance with the SEBI Rights Issue Circulars, the Eligible Equity Shareholders, who hold Equity Sharesin physical formas on Record Date and who have not furnished the details of their demat account to the Registrar or our Company at least two working days prior to the Issue Closing Date, i.e. Friday, January 27, 2023, shall not be eligible to make an Application for Rights Equity Shares against their Rights Entitlements with respect to the equity shares held in physical form.

PROCEDURE FOR APPLICATION: In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Ci

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from

any other source may make an Application to subscribe to this issue on plain paper with the plain paper with the same details as per the Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorization for blocking funds in the Application Form, as the case may be, at the time of submission of the Application.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH SHAREHOLDERS ON THE RECORD DATE I.E. APRIL 10, 2023.

APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARESIN PHYSICAL FORM: Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI ICDR Regulations read with the SEBI ICDR Regulations. holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

They may also communicate with the Registrar with the Registrar with the help of the helpline number (022-6263-8200) and their email address at rights issue@bigshareonline.com.

DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM: The Dispatch of the ALOF, the Rights Entitlement letter and Application Form for the Issue has been completed in electronic mode through email on 24thApril, 2023 and physically through registered post on 27thApril, 2023 by the Registerer to the Issue. CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shareholders which would comprise Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entitlement Suspense Escrow Demat Account (namely, "Earum Pharmaceuticals Limited Rights Entit (namely, "Earum Pharmaceuticals Limi Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shares held in the account of the IEPF authority; or (b) the demat account to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional

equity shareholders in the United States. APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS: An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application to the Designated Branch of the SCSBs for authorizing. such SCSBs to block Application Money in the said bank account maintained with the same SCSBs. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address or is a U.S. Person or in the United States.

Please note that the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The application on plain paper, duly signed by the Eligible Equity Shareholder, including joint holders, in the same order and as per specimen recorded with his bank, must reach the office of the Designated Branch of SCSBs before the Issue Closing Date and should contain the following particulars:

 Name of our Company, being Earum Pharmaceuticals Limited: Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);

Folio Number (in case of Eligible Equity Share holders who hold Equity Shares in physical form as on Record Date) / DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shareholder and for pursuant to this Issue

5. Number of Equity Shares held as on Record Date;

Allotment option – only dematerialized form; . Number of Equity Shares entitled to:

8. Number of Equity Shares applied for within the Rights Entitlements:

Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for); 10. Total number of Equity Shares applied for;

 Total amount paid at the rate of Rs. 21- per Equity Share; Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;

13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NREFCNR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder lin case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

All such Eligible Equity Shareholders are deemed to have accepted the following: "If We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

If We understand and agree that the Rights Entitlement and Rights En

If We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations. If We acknowledge that the Company, our affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account, as application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Shareholders. The plain paper Application form at will be available on the website of the Registrar at www.bigshareonline.com.

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date. LAST DATE FOR APPLICATION:

The last date for submission of the duly filled in the Application Form or a plain paper Application is 31st May, 2023, i.e., Issue Closing Date (onclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSBs, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSBs on or before the Issue Closing Date or such date as may be extended by our Board or any committee. thereof shall be at liberty to dispose of the Rights Equity Shares hereby offered, as provided under the heading "Terms of the Issue-Basis of Allotment" on page 142.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchanges.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number. PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market Renunciation Period. The Shareholders should have the demat Rights Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in the Rights Entitlements. Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholder son or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchanges through a registered stock broker in the same manner as the existing Equity Shares of our Company. In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INED60620015 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from

the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchanges from time to time. The Rights Entitlements are tradable in dematerialized form only. The market for trading of Rights Entitlement are tradable in dematerialized form only. The market Renunciation Period for On Market Renunciation, i.e., from 2nd May, 2023 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements available in their desired to trade. The Shareholder scan place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat

The On Market Renunciation shall take place electronically on secondary market platform of BSE Limited under automatic order matching mechanism and on 'T + 1 rolling settlement bases, where 'T' refers to the date of trading. The transactions will be settled on trade for trade basis. Upon execution of the order, the stockbroker will issue a contract note in accordance with the requirements of the Stock Exchanges and the SEBL

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the Rights Entitlements who desire to transfer their Rights Entitlements who desire to the Rights Entitlements who desire the Rights Entit receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

ELIGIBLE EQUITY SHAREHOLDERS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS THROUGH ON MARKET RENUNCIATION, OFF MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE RIGHTS EQUITY SHARES. IF NO APPLICATION IS MADE BY THE PURCHASER OF RIGHTS ENTITLEMENTS ON OR BEFORE ISSUE CLOSING DATE THEN SUCH RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO RIGHTS ENTITLEMENTS WILL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. WILL LOOSE THE AMOUNT PAID TO ACQUIRE SUCH RIGHTS ENTITLEMENTS.

FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 1290F THE LETTER OF OFFER.

Subject to receipt of the listing and trading approvals, the Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights basis shall be listed and admitted for trading on the Stock Exchanges. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights Equity Shares Allotted pursuant to this issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

For an applicable period, the trading of the Rights Equity Shares would be suspended under the applicable law. The process of corporate action for crediting the fully paid up Rights Equity Shares to the Eligible Equity Shares would be suspended under applicable law. The existing Equity Shares are listed and traded on BSE Limited (Scrip Code: 542724) under the ISIN: INEO60601023. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing approvals, the Equity Shares shall be debited from such temporary ISIN and

credited to the new ISIN for the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchanges, we shall refund through verifiable means/unblock the respective ASBA Accounts, the entire monies received/blocked within foundays of receipt of intimation from the Stock Exchanges, rejecting the application for listing of the Equity Shares, and if any such money is not refunded/ unblocked within fourdays after our Company becomes liable to repay it, our Company and every director of our Company who is an officer in-default shall, on and from the expiry of the fourthday, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law. DISCLAIMER CLAUSE OF SEBI

The Final Letter of Offer has not been filed with SEBI in terms of SEBI ICOR Regulations as the size of issue is below Rs. 5000 Lakhs. DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE):

As required, a copy of this Final Letter of Offer has been submitted to BSE Limited. The Disclaimer Clause as intimated by BSE Limited to us, post scrutiny of this Final Letter of Offer is set out below: "BSE Limited ("the Exchange") has given, vide its letter dated March 2, 2023 permission to this Company's securities are proposed to be listed. The Exchange's name in this Final Letter of Offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:

I. Warrant, certify or endorse the correctness or completeness of any of the contents of this Final Letter of Offer; or ii. warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or

and it should not for any reason be deemed or construed that this Final Letter of Offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be

iii. Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

suffered by such person consequent to or in connection with such subscription lacquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever." Neither the delivery of this Final Letter of Offer nor any sale hereunder, shall under any circumstances create any implication that there has been no change in our Company's affairs from the date of such information. Each person who exercises Rights

Entitlements and subscribes for Equity Shares, or who purchases Rights Entitlements or Equity Shares shall do so in accordance with the restrictions set out below. In accordance with the SEBI ICDR Regulations, the SEBI Relaxation Circulars, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent / dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of

Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian

Further, this Final Letter of Offer will be sent / dispatched to the Eligible Equity Shareholders have provided their e-mail address, the Letter of Offer will be sent only to their valid e-mail address and who have made a request in this regard. In case such Eligible Equity Shareholders have not provided their e-mail address, then the Final Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Final Letter of Offer, the Abridged Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of: (I) Dur Company at www.earumpharma.com;

(ii) The Registrar at www.bigshareonline.com; (iii) The Stock Exchanges at www.bseindia.com.

2. Off Market Renunciation

Eligible Equity Shareholders who have not received the CAF may apply, along with the requisite application money, by using the CAF available on the websites above, or on plain paper, with the same details as per the CAF available online.

Eligible Equity Shareholders can obtain the details of their respective Rights Entitlements from the website of the Registrar by entering their DP ID and Client ID or Folio Number (in case of Eligible Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company. Further, our Company will undertake all adequate steps to reach out the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

BANKERTO THE ISSUE AND REFUND BANK: AXISBANK LIMITED

MONITORING AGENCY: Not Applicable

Listing and trading of the Equity Shares to be issued pursuant to this Issue

FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF. OTHER IMPORTANTLINKS AND HELPLINE:

The Investors canvisit following links for the below-mentioned purposes:

Frequently asked questions and online / electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: www.bigshareonline.com Updation of (e-mail address) phone or mobile number in the records maintained by the Registrar or our Company: www.bigshareonline.com

Updation of Indian address by way of sending an email to www.bigshareonline.com Updation of demat account details by Eligible Equity Shareholders holding shares in physical form; www.bigshareonline.com

Submission of self-attested PAN, client mastersheet and demat account details by non-resident Eligible Equity Shareholders: www.bigshareonline.com

REGISTRAR TO THE ISSUE BANKER TO AN ISSUE BIGSHARE SERVICES PRIVATE LIMITED AXIS BANK LIMITED Address: Shop No. G1 and 2 Swagat Plaza, GroundFloor, RadheyKishan Residency, IskonAmbli Road, Ahmedabad – 380058 Pinnacle Business Park, Office No S6-2, 6th, Mahakali Caves Rd. Next To Ahura Centre, Andheri East, Mumbai, Maharashtra 400093 Tel: 022 - 6263 8200 Email: rightsissue@bigshareonline.com Tel: 8758474645 Website: www.bigshareonline.com Email: iskonambliroadahmedabad.branchhead@axisbank.com Contact Person: Mr. Veay Surana Website: www.axisbank.com Contact Person: Devang Taunk and Sagar Vaidya CIN: L65110GJ1993PLC020769 SEBI Registration No: INR000001385

Date: 27th April, 2023 Place: Ahmedabad

For, Earum PharmaceuticalsLimited Madhuri Mistry Company Secretary

Kolkata

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with Stock Exchange i.e. BSE at www.bseindia.com and the website of the RTA i.e. Bigshare Services Private Limited atwww.bigshareonline.com. Eligible Equity Shareholdersshould note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 24of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sale in any jurisdiction, including the United States, and any Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sale in any jurisdiction. Rights Equity Shares in the United States.



The absolute payment with an intermediate payment with an intermediate an amount of the an intermediate and associated in the second of the antique and the second of the antique and an intermediate and associated in the second of the antique and an intermediate and associated in the second of the antique and an intermediate and associated in the second of the antique and an intermediate and associated in the antique and associated in the antique and associated in the antique and an intermediate and associated in the antique and associated i

- ERRUM

EARUM PHARMACEUTICALS LIMITED

On Example and subjectly the results of a 1/2 of 2, 27 (2 of 2 from Proceedings in the State | 1 from Proceedings | 1 from Proceedings

* Digital Carly Americalism are requested to conscribe the strengt of consists from the constitute the section of the section

The state of the s

The state of the s

PROCESSE TO A PROCESSE procedure with Equation That the 2011 Distriction, the 2011 Distriction, the 2011 Distriction of the National Association in the Section of the Sect

PRINCIPAL PROPERTY CONTROLLED STATE OF CONTROL ST

age for the complete property of the complete

Or Creams softin Bagbier de Laury alters ress arrellativos.

If the policies has the standard with a SCAN, wheater with the things and the policies have be the SCAN to a chainer in how bring these and the standard policies have been a standard by the standard policy of the standard policy

The second secon

to the property of the control of th

The Marrienters bridge the Maries for Marries for Maries for these to refer that Maries for the way of the second or the Maries for the Maries of the Maries for the Maries

AND THE PARTY AN

ly Maus on third on trains on TRE. Latter State State SATURE and the MERCHARD STATE State May aimly to collect a recognizery MERCHARD State and the Collect State State

ida in sinda finding ar valleng mendende benering Bande Comburges, om sind rekner i tansaga mer little remembalisat i kar requestra ARRA America, the performance of the little benering at fraction for the desiration for the little benering at the little benefits and the little benering at the little benering at the little benering at the little benering at the little benefits and the lit

The Paul Latinor Office Institute of the Contract of the Contr

dad by 1916 Limberton ay part arratiny of this Famil Later of Offen beart and below: On Endough's count in this Famil Later of Offen an own of the stank analogue arraphish this Company's countilise are prop "1917 Under ("The Perlange") has given, which is better should five in 2, 2028 pe perulation to this Commun. The Endourse story set is now manner:

ed i decident for any mende formed a markent for the first form of this has been shown in generally the Enrique Deep process who delives to grave the content of agreement of the Deep process of the Content of the Deep process of the Content of th

ngeny's official input for data increal or the data of each information or that the in Middler the delivery of this Proof Letter of Cities are recycle improving, shall ender any discountering as experience implication that there has begun a sharing in one Californian and relate than the Emply Boson, as subspectimen Rights Endowment or Emply Boson and do so in accommon relation reside form and and incom-Filter than the control of the part of the

ler, this Plant for any filler will be used fragments the Egible justy Shouthaften who was problem justice and who becomes a request.

The Blant for all forms of the will be deposited as a recommendation, it devices a first and any problem for the second and any problem. The second and the becomes a request of the second and the secon

Dote: 17th April, 2023

th Epily Sandallan wis lowest moteral in CAT regage), steep with the applicate same, by using the CAT residels on formation above, or as pile pape, with the sandalland paper for CAT residels on the CAT residels on the CAT resident of the CAT resident of the Sandalland on the CAT resident of the CAT reside

POR BUTCHET THE AND COMES DETAINS ASSESS TO THE LETTER OF STREET AND ALONG

Angele place of the property o

WATE THE STREET THE RES (1974) SENGIAL PRIMACES PRIMACE LIMITED
Primach Institute Park, Silks No 60-5, 600, Ministral Cores Hd, Sent To Albert Corins, An
Tel 1022—1023 2008
Exact Collection (Manhamathan, 201) Address: Drug So. 61 and 2 Brought Plans, II Laborated Broy So. 61 and 2 Broyal Plans, II Laborated Broy Advantage - 200 MB Panels Contract of The Series

بالز إساسا





EARUM PHARMACEUTICALS LIMITED

Company on any planty income reason and the SECTION OF THE COMPANY OF T

A top 1 pt 1 feet of the second of the secon ng ayun, Walgaliya memunyangkamayayan, Cantang Parayam Mrs. Madhad Milatry, Campany Sepretary and Campilanay (Milatr 11'84, 80 I' Mrs. Mill

* Big to the processing or requested to compare the compared on the contract transfer to compare the compared to compare the contract transfer to compare the compared to compared to compare the compared to compare the compared to compared to compare the compared to compare the compared to compared to compare the compared to compare the compared to compare the compared to compare the compared to compare the compared to comp

CONTROL CONTROL AND AN I AND AN AND AN AND ANALYSIS AND ANALYSIS AND AN ANALYSIS AND AN ANALYSIS AND ANALYSIS ANALYSIS AND ANALYSIS ANA

many, females, Spile Lasty Corners

tenters, the Flights Equity Shouledides, who held Equity Sh the report to the english starred belief, plants allegs, مدا داری (۱۱ اید) ۱۰ اید) داری (۱۱ اید)

STATES OF THE ST

ACTION CONTROL AND INTERNATIONAL PROPERTY OF THE PROPERTY OF T

Burn des Course (de la Communication (de la communication (de la communication de la communication (de la communication (de la communication de la communication (de la communication de la communication de la communication (de la communication de la communication de la communication (de la communication de la communication de

s. address und imme of the extremit ACAS: discretifs as belles address, disclore (the INTEGENETATION construction in the account and appropriate for the Application Manager than difficience and the ICAS; and

e production for the original state of the control Brown which way in required by solving judicilation or early way all reconstruction which such after or each is not entire to The substitute of the supplied by the substitute of the substitute

et kieldig sine sinete ku Maradaldira is kundundari.

vi mil Mijdir kapit Planer may ni kernelleri di, senial,
evant il seriad en supil lig such Nijdir Entlitesani and
entli seriad en supil lig such Nijdir Entlitesani and
entli stare sillining sparit limit tenti mat successory et lim bira Starit di Application periodologia Piglica Sellissania an
entlinin sillinin sillin sillinin sillinin sillinin sillinin sillinin sillinin sillinin sillinin rdende berken myt is elden bereitet myten eit byside t. ordende promit is enegte bra et et mente et diste bekein misde sente Distrikturet en stel is 1.0. Entworte "A. Poor" withelt i Pouties", mill is en materia fisht bittemant ein lich beit ine berfier

Backeline-contention in the process of the hydrother are not epicially for SEE or back on an ideal of the incommendation for the process of the hydrother are not epically for SEE or back on an ideal of the incommendation for the incommendation in the incommendation

Commission of the Commission o

d to Reak Indonesia of Antifel (of the last inspectation in the last of the contract of the

ly finalaten respekte komm fin sundets tragbet unde hade komplet in met a navette tragbet blima i somet et ist in dentember om et ist in beskendet bli i sundenskap bli i tragbet blima kan bet i som et in sundenskap blima i som et in sundenskap blin

gibida prin. Di daliyar in ligili iyin (kururudi in mpuni dan in mpirin in . Ta provi dapa siste in redikin in Mpiri a pipi iyin kururudi ka mpuni dan in mpirin in . Ta provi dapa siste in redikin in Mpiri a pipi iyin kururudi. Mpirin ilka un hida ali rini a Milita jira in 1925 siste in Milita in Mpiri a mpirin a mp

Life of Windows (Annual Control for the Street Control for the Stree

t, and to a many transaction of many and making the best of the first of the second of the

that in an own induced a computing the last later of the pulses down required by the Endage Decreases and investigating a standard polymers and the Coniene efficie filmi Luffer of Ofer see my milulamenter, stell maler my chromatoccus-courie see implication film of admirtion for Egolly Manna, erade-portnesse Physic Euffernatio or Egolly Massaultad de et in accordance e

H (PACALITY OF THE HET THE ASSESSMENT AND ADDRESS OF THE ASSESSMENT ADDRESS

tile flad Later af Cifer-ellin enskt departens he fart lighte Englis flamheldersvele hans perdied hellen elleren . Den tile flad Later af Olive-ell te dispatcioni, oca renemble etter lands, to tile hellen ellerense protéed by dans.

yndd da saphlys gyfladio sawy, ly sŵy da EU Andellon fwraholas alon, ar aglebygau, eith feannadach as ar la EU Andellon d Fellomet i mallweinio f fellogiaeth y maley bei FEU ar Electio o hei Benley fa am i fellofikhjin). Yn dallor biblioghig fel Maley Benleydd winner yn dy hei Andellon Fellog fellog ferwan, a cryf yn heill.

E MATO TE COME	LIGHT TO AN EVEN
Politic Michigan Profes Th Later Lab uch Switzen Profe, Mithelia COST, Dile, Michigan Coppe Mr. Marci To Alarm Contro, Justicolliste, Michigan, Michigan Collecti	ACT MATE LINET DE Chirac Barile, II ou Thurst Fee, Branding, Baller Chiralistics.
127 - E204(207)	Interior State State
the row lighteening and	Control of the last t

No.276 April 2023





entiation to punitions, to held or self-attention. This is not on assessment or the offer-determine. All cop--(LDFT-file) with the DMI Labout (1987).



EARUM PHARMACEUTICALS LIMITED

On the second state of the MICH MORE

After the second of the second second

Plane part facts recording with hydright 270,4 for SSM 1500 hydright and old the SSM hydright sens Control for the Statement and distinct of Fig. 1 and 1 an

William Control of the Control of th

THE SECTION AND ADDRESS OF THE PROPERTY OF THE

THE RESIDENCE OF THE PARTY OF T MICHOLINENINOS THE RECORD OUTE UE, APPUL 10, 2003.

The second secon

Fris Layler to Pear is not related with an STMs, quinted with the State Parlament of the State of the Market to the STMs or a before to some Co.

The parlament of the State of the State State State of the State State of the State of the State State of the State State of the State State State of the State State State State of the State State

The Control of the Co

entralista in programme de ligion politicare, contrate estate inspector form consense by mellinghilling throw the mendator parties of the State Parlament design is applicated as an interest that is a consense or incombing lighty flower or in the state of the State Parlament or interest that is a consense or incombine to the state of the State Parlament or interest that is a consense or incombine to the state of the State Parlament or interest that is a consense or interest that is a state or interest that is a state or interest that is a state of the state o

S. M. Brist Brownisten

The formation of the first of t

OF STYLEATING OF BUSINESS NUMBER OF STREET

Adjarin nasjari di krisya i kulig gyyeri, ita ligit (Krosyyeri i shishani an dirinda da kalimi kulimi kulim

The making from Miller State of the Control of the

The Part Later of Mile Institute Market 1990 is smooth 1990 Care registered as a surrounding to the Control of Market 1990 is a surrounding to the Control of Market 1

. Divieri, cordiformations discorrections recognisions of separatic contents of this first latin of Mile; or provide the this Corporat Locarities of the Senior reflectation to be Employees in Employees

agent or one consensus. A Propy process or include or in agenty has not result part to increase all hards or list step other altery of the Paul Later of Offer or my sels homestes, deliberate my elementarem mente my hydrodien that there has been as shought on f yest principality in Egilig Manas, or wis produced lights Extilization or Egilig Manas shellds at happenings with the egilights as at set being.

Territor, view of the set of the configuration is the lighth hely. Bushisher wis has provide taken orders as who have cause by the report, some and lights hely. Bushisher who have been and to be support to the set of the light hely bushisher the provided having and by these causes are provided by the light have been as the light have been applied to be the light have been as the light have been applied to be the light have been as t

Sandalin an arms Maffeel Later of life, do Mai de Carlomage of wore prophoson con: At the Registry of wore instruments and con-traction of the Carlomage of work making one.

v, ar Campany all-valleraise disclosure records aspective Ri nor to you communicate service sales aspective the section of the Tableto in COCCUS of Application

NÎN MINI TRACIONA AND ÎNIÎN DET ALA, CHIN Y REPRI TÔ THE LETTER ÎN ÎNTRE AND ALÂN O men movem l'authemic ann e câpaire

And the second section of the second section is a second section of the second section of the second section is a second section of the second section is a second section of the sect

MANTENET TO THE MANE	NAMES TO ALL RAVE
Beddished extractors in Particle (Indit To). However, Prof. (Alley in the California (India) (Alley in the Care Coming, Andhori Baye, Marriage (Montage) (Montage) 10: (107.—400) Caste 10: (107.—400) Caste Machine (Montage) 10: (107.—400) Caste Machine (Montage) 10: (107.—400) Caste 10: (107.—400) Ca	ACTIVE STATE IN LATE TO A TOTAL T

144,900 144,900



EARUM PHARMACEUTICALS LIMITED

De Company una migliori piecemperiori un July 20, 2712, un "anuar Phonoconticuis Private Lindica" un a Private Lindica Company under Ten presidente de Company un descriptor de Company un descriptor de Company un de Company un de Company un descriptor de Company un descript ion of the Companion Set, 1965 a Africa Register of Prospecto, Refered Misson Street Street Street Sources van convenient de prints (Arrive communication accommente Public Street Companyon Louise St. 1976) de Sachty of Companyo, Alexandra, Sector,

Corporate Manifesting Manifest (1997-1971) 197-1971 (1998), Replacing Office 6 1 1981, Explain Matter Tails, School City Book, Manifest 5 1981, Address 1 1981, September 1 19		
PRINCES OF THE CHIEFLES AND ADDRESS AND AD		
nicae in control	LAST ENTE FOR MUNICIPALITY MERCULATION	mine Clotes for"
2" May, MESS	20° May, 2023	11° May, 28/23

This is the first of the second to make the consideration of the second to the second

Margin, Rain, Brass, very of Application - Main smaller!!

"Application Represed by Martine demonstratible in a believe very of applying to bessed by Marting allowed account, become a property through the last better account, become a property to the property of the last account, become a property of the last account, account, become a property of the last account, become a property of the last account, a

Addition of the second of the

day Date, the Highle Pathlements of France

APPLICATION OF CANADA SPINITY PROCESSION OF CONTY PROCESSION PROCESSION FROM THE CONTY PROCESSION OF THE CONTY PROCESSION OF CONTY PROCESSION OF THE C

ASS ANY DESIGNATION OF THE STATE OF THE SHAME DEPOSITION AND TO THIS WAS DEPOSITION ASSOCIATED WITH A WASSACRED FROM THE

in dari in Elglin Ensiş Mandalları adır ve malay ile Applicative ve pide paper stalları besa Kallınmalak paper, interdenci ir ile Elglin Ensiş Mandallak, İstalian İstal İstilen, İstil ve ve nete and visuali antendiar the depoleration from the may progress including recompletions one I'll in combined extension of the land of th

Andread of the control of the contro

mid, belga a allumba kundani magda sa Alibas kumadada magdam alik Aspialaa I, o alimaka permad kara mina hama kara katika ka karajisa kara

Last Not recovery the recovery the recovery the recovery of th

The second secon u diel leis piec caty deleg ils Hamachillu Palas (ar Va Hindellinauchillu. La. Tru Zai II. El 1676/2017 (mai leisallag les deble al die Ugles Estitumen des labes in trais. Tie B

rechalle or consider mathefullation of MIS (Instrument and color matheful considering and on T + Institute artific

i Bernalden og som en folkjellet Bernat, millet i der ogsån som ennest popyter i Franke varke kompt i spektop prikjer. To bljet i folklende om beskelle beskellet for i Franke om en som en forså bligde folklende om en forså en folklende om en forså bligde folklende om en forså bligde folklende om en forså bligde folklende om en forså bligde folklende om en forså en folklende om en folklende

The second section of the second section of

ndig die light (all) Finn hauf gemail die besoeld is besie die eersteplieb, bezeitigt, system is die gebeite gebend die beliet as 'ndig stade'. Die besoelde gewone die besie is daar besoel gegen die deer kompte die besoelde di

College Colleg

Security or advice the community completions of any of the common of the Hall committing or names therein Engage a committee will alread or off confirm who had no the Bubbags or

n indused a material this fluit later (Oferlandon sinus enganed by the bullage Encycons who have to gold for a standardon separate to a manufacture of the standard for the stan

odrium eftin Plat Laike of Ofer an any existements, shall salar any elementarior over explantia the time has been as sissue is our fa-transferior for Egylig Same, or abspectuare Papin Erikannik artigally Samu and das in monther-order or articles and an index. . Antonial w the defeat man information or Statistics in Committee

A CALL STATEMENT AND AND ADMINISTRATION OF THE PROPERTY OF THE

Police, the Police of Clincal installation in the Sight halfs Send allowed research with a sight of the sight send of th

graffi fir sapilit, spilletin man, iş miş fir CVF mildib ertir mildik den, ereşinişeye, vili firemeditik sışırtır. LVF safinis ad Feldinmes franksıdırı feldişine iş şeniş birlifik ad Filmi'de film balak iş ana if Ajibilya, Filmidice birlişdiye, birlişdi. İsk birliş Amalika ve ine yerini dik eldin aldır den geliği dereme, arşıfı balik.

Parlin, or Congrey off university of object bearing an extra parling for faithful and object bearing the control of the contro

Promotes a sea recorded to the seasonal designation of the recorded restriction of the recorded recorded to the recorded recorded to the recorded recorded to the recorded to		
	RESTRUCTE NOTE	Parametry of Provide
	BOOODANCOCTACOTA (1974) TELEMENTO Primote Politore Park Olitor Goldol, On. Medicinal Curve Int. Nact Te Alares Contra. Andirollinst. Mondes. Minimunity 901001 Ed. 607 — 125 May 1974	4.50 high LMBT'S Lidents: Style, F. Fran Zivegyd Plan. Trendfirez. Enthryfithendistrinay. phenically Res. Ferminar - 20100
	White provide the state that the sta	The FT SEA PARK STATE OF THE SEA PARK STATE
	and the same of th	Qualityal Principe: Spring Type and Steger Schiller

Brissi Pri. Spril, 2003 Plane Manageria

This principles were to be informative progress only and storage and storage and storage and storage and storage and storage in turn in the latter of order in the latter of order in the latter of office and storage in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn in the latter of office in turn



EARUM PHARMACEUTICALS LIMITED

The second section of the Second section of m.cov, Gantoni Prancos Mrs. Madinal Miniry, Gangary Picrotory and Gangdi

I, Tringinum + ETFAMCZSS; Sted Manifestropherocam, PORCESSA PATTEL AND MINI, PARIA SERVICES PATTEL 11°Mm, 202

Topics in the property of the control of the contro

Mangia, Barle, Sanare vary of Application - Mathematel Will.

"Application Separated by Mandal James (ASSA) is a feature way of applying to home by about yithinking first and be the bank of

and the plants of the ball (CE) in plants and the plants are proportionally and the plants are proportionally as a proportion of the plants are proportionally as a proportional property of the plants are proportionally as a property of the plants are proportionally as a property of the plants are proportionally as a property of the plants are

per Spira version Peris, ils Rigido Estillamento el disco i er la llacon Upuning Peris, ils Rigido Estillamento el disco il erus Sancot Sancon Spirato — 1 277 (1976) (1976) merinan vilk da 350 ligita iaun Emaira, in Figila Iyaly Sandalder, ola inid Eyaly Sarvala physical Amus sa Ras ru apdari ikel: Rigita Estilianute aldarupet ir in ryalydareshalda physical isus.

18 Martin Constitution of Constitution (Constitution of Constitution of Consti

17. The Control of th

and of Paramy, this firm to provide the second state of the second

al Emily Survey activity to Topic Survey applet for artifaction lights Entitlements of machine is party flavor against to the machine substitution algebraichte.

in the second second second second second second second second second second second second second second second Second se na Migha ignity them may not be nothernous on rept reported for borth pages 10 highly them may not ment authorised or to cap per at Migha ignity them may not be nothernous, much public or alternative treatment encored on a theoretic encountries with insulative constraints. At the complexity of the contribution of the light in the contribution of the light in the contribution of the light in the contribution of the light in the linterest in the light in the light in the light in the light in th

of participation of the Register shall not be a part participation or you have the

the Application Form to art a should with the SECUL, against with the Secul Techniques and the Application Honey's met blacked with the SECUL on a button the team Charley Date or much in Arrival and to at Monty to dispose of the Highest Explay Wasser broke of Form, as well as broken Form of Advanced" on page 142.

1. All principal processed in the control of the co

. 64 Materilanentales In Shirk Suits Servician serv

questions a region in over intermedian languel audici curb à majoint la mission distribut la literature en la faction de communication de major de la literature en la faction de la literature en la literature en quie à distribut de la literature en la literatur

angeletigend, de bedag i delligie (gr.); Some allementario de la completio del la completio della completio della completio della completio della completio della completio della completio della completio della completio de

appear to the part of the part

/ 350 CCC Regulation on the departments below to ACCC failed

In the supposed of the second

MATERIAN AND THE STATE OF THE S

reflect till store for between til som programmer. Det store for for the store of t

RECOFFINATO TO THE MARK	SARRES TO AS MADE
Special Action Control of Con	ACRE NAME LIMITES department from (b. C. T and 2 brought Frame, broadforet, FaultspitChindripathinery, Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA) Track (1982 A SAA)
Reju(Cris April, 2015) Pierr: Assentiani	For, Corpus Phyrocoppodigodyl Ind